MEDTECH/ DIAGNOSTICS

COVID-19 has ushered in a tremendous increase in awareness about health and wellness along with underlining the utility of home-use diagnostics tests and newer medical technologies.

‘Saw very strong demand for Versius’

“In 2021, CMR has performed exceptionally well. The company has celebrated a number of key milestones, including our recordbreaking $600 million Series D raise, a number of advanced and large market launches of surgical robotic system Versius including Germany and Australia, new regulatory approvals in high growth markets such as Brazil, the strengthening of our leadership team and the expansion of our manufacturing output, with plans to build a new global manufacturing facility to meet the growing global demand for Versius. We are on track to meet our commercial targets and have grown our commercial presence to more than 20 countries globally.”

- PER VEGARD NERSETH

Chief Executive Officer, CMR Surgical, UK

‘New hires increased by 30 per cent’

“Our products are used in research & clinical laboratories around the world, contributing to COVID-19 quality screening assay and antibody tests. Our 2021 Q1 to Q3 revenues increased nearly 35 per cent from 2020 Q1 to Q3. Our new hires increased 30 per cent and nearly all the manufacturing spaces were fully utilised.”

- FRANK LIN

President, General Biologicals Corporation, Taiwan

‘Increased edu opportunities for endoscopists’

“The pandemic has accelerated and advanced our initiatives to globalise our workforce and reinforce digital customer communication and support. Soon after the pandemic started to prevent face-to-face business communications, Olympus introduced IT environments to enable most of our employees to work from home. Thanks to the great efforts and flexibility of our IT team, we dramatically improved our meeting and decision-making processes and accelerated employees’ collaboration across

countries. We have also enriched our online training platform for healthcare providers which has helped us expand our outreach to doctors in remote areas and increase education opportunities for endoscopists.”

- YASUO TAKEUCHI

President and CEO, Olympus Corporation, Japan

‘Acquired Hitachi’s diagnostic imaging business’

“In addition to supplying antibody test kits that can detect even small amounts of virus, ultrasound systems for diagnosing pneumonia, and mobile X-ray diagnostic equipment, we are also providing contract manufacturing of vaccines and advancing the development and manufacturing of Avigan Tablets as a therapeutic drug candidate. In spring 2021, we welcomed Hitachi’s diagnostic imaging-related medical business to the Fujifilm Group. This addition allows us to provide even more tools to support physicians and clinicians in diagnosis and treatment with expanded offerings including CTs, MRIs, and other devices, and leveraging Fujifilm’s cutting-edge image processing technology with AI/IT to improve clinical outcomes.”

- TEIICHI GOTO

President and CEO, Representative Director, Fujifilm, Japan

‘Launched India’s first high sensitivity Hep C kit’

“Transasia further strengthened its COVID-19 testing portfolio by launching ErbaMDx COVID-19 RT- PCR kit with five times greater sensitivity to detect even low viral load. Besides this, we recently introduced ErbaLisa HCV Gen 4 Ag+Ab, India’s first and only indigenously developed 4th generation ELISA assay for detection of Hepatitis C Virus. It is intended for early detection of Hepatitis C infection. We also introduced the ErbaQik rapid test kit for four critical infections namely HIV, HBsAg, HCV and Syphilis. These kits provide results in 20 minutes and have been approved by National Institute of Biologicals (NIB), Pune.”

- SURESH VAZIRANI

Founder Chairman, Erba Transasia Group, India